Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Highly experienced ex-Delta One trader with 17 years of experience trading arbitrage and related strategies across Asian markets.

Exempt Financial Adviser (EFA) under CrossASEAN Research Pte Ltd.

It is important to note that the information provided by Periscope Analytics is based on publicly available data and own knowledge, which has been gathered and synthesized from a variety of sources. While every effort has been made to ensure the accuracy and completeness of the information provided, it is not guaranteed to be free from errors or omissions.

All forecasts and estimates are based on information that has been obtained from public sources that are considered to be reliable. The sources include, but are not limited to, company announcements, exchange filings, ETF and other passive investment vehicle holdings, and free float and volume data from third-party data providers. Periscope Analytics does not guarantee the accuracy and completeness of the forecasts, estimates and/or other information.

Pan-Asia Index Rebalances/ Events/ Delta One

Taiwan Top 50 ETF Rebalance: Another Inclusion for Caliway Biopharma & King Slide

Chroma Ate (2360 TT): Double Index Inclusion Coming Up with Plenty to Buy

Taiwan Top 50 ETF Rebalance Preview: Plenty of Big Overlapping Flows Coming Up

Yuanta/​P-Shares Taiwan Div+ ETF Rebalance: Huge Turnover & Flow Overlap

King Slide Works (2059 TT): Sliding into a Global Index

Taiwan Top 50 ETF Rebalance Preview: Another Inclusion for King Slide

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Index Rebalance

Caliway Biopharmaceuticals / Index Rebalance

<ul>
<li>There could be 2 changes for the Yuanta/P-Shares Taiwan Top 50 ETF in September - both changes are high probability.</li>
<li>
<a href="https://www.smartkarma.com/entities/caliway-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:44038:1" rel="noopener">Caliway Biopharmaceuticals (6919 TT)</a> and <a href="https://www.smartkarma.com/entities/king-slide-works-co-ltd" target="_blank" data-smartkarma-citation="entities:7130:1" rel="noopener">King Slide Works (2059 TT)</a> are being added to a global index at the close today and are potential inclusions to the ETF in September.</li>
<li>
<a href="https://www.smartkarma.com/entities/caliway-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:44038:1" rel="noopener">Caliway Biopharmaceuticals (6919 TT)</a> will also be added to another global index at the close on 19 September, so more passive inflows for the stock. Reversion thereafter?</li>
</ul>


There could be 2 changes for the Yuanta/P-Shares Taiwan Top 50 ETF in September - both changes are high probability.

Caliway Biopharmaceuticals (6919 TT) and King Slide Works (2059 TT) are being added to a global index at the close today and are potential inclusions to the ETF in September.

Caliway Biopharmaceuticals (6919 TT) will also be added to another global index at the close on 19 September, so more passive inflows for the stock. Reversion thereafter?


Taiwan Top 50 ETF Rebalance Preview: Hat Trick for Caliway Biopharma?